



# TECHNICAL BULLETIN

Bureau of Clinical Laboratories, Sharon P. Massingale, Ph.D., HCLD/CC (ABB) Director

July 22, 2024

Volume XXIV Issue 8

## ATTENTION ALL PROVIDERS



### TB Susceptibility Testing

- Due to a manufacturing issue, *Mycobacterium tuberculosis* pyrazinamide (PZA) susceptibility testing was ceased as of July 22, 2024.
- The BCL will continue to perform susceptibility testing for streptomycin, isoniazid, rifampin, and ethambutol.
- At this time, the manufacturer has not given an anticipated date of resolution.
- The BCL is working with the CDC to provide *pncA* sequencing for priority TB specimens.
- The BCL will inform you when we are able to resume PZA testing.

For questions regarding this bulletin, contact the Mycobacteriology & Mycotics Division at 334-290-3089.

**Alabama Department of Public Health  
Bureau of Clinical Laboratories  
204 Legends Court**